enGene Holdings Inc. announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws joins enGene with nearly 25 years of life sciences-focused operational and deal-making experience. Prior to joining enGene, Mr. Daws was Chief Financial Officer and Head of Business Development at Obsidian Therapeutics Inc. In that role, he was responsible for finance, business development, information technology, investor relations and facilities functions.

Prior to joining Obsidian Therapeutics, Mr. Daws was Managing Director with the Healthcare Investment Banking Group at Robert W. Baird & Co. Inc. where he was responsible for IPOs, follow-on offerings, private placements and mergers and acquisition transactions in the life sciences sector. Mr. Daws also previously served as Chief Financial Officer and Head of Business Development at Concert Pharmaceuticals Inc. Prior to Concert Pharmaceuticals, Mr. Daws spent nearly 15 years originating and executing equity and mergers and acquisitions transactions in the life sciences sector, first at Cowen and Company, LLC and then Stifel, Nicolaus & Co Inc.Mr. Daws earned his International Master of Business Administration and Bachelor of Science in Business Administration from the University of South Carolina.